Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BRCA1 breast cancer test could be ready in 1-2 years, Myriad Genetics exec maintains.

This article was originally published in The Gray Sheet

Executive Summary

BRCA1 BREAST CANCER DIAGNOSTIC TEST FOR HIGH-RISK WOMEN could be ready for the market in one to two years, Myriad Genetics VP Mark Skolnick, PhD, asserted at a Feb. 14 American Medical Association press conference on genetic cancer findings. "We feel a mutation-based diagnostic can be ready in one or two years which would be appropriate for a high-risk population," he said. The test would be limited to a high-risk population, i.e. women with breast or ovarian cancer or their close relatives, Skolnick added, because the product "would be expensive."



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts